An EXSCEL mediation analysis finds conventional risk-factor changes explain only part of exenatide’s cardiovascular benefit and do not mediate its mortality effect. PICO summary and commentary.
Browsing: Cardiovascular
Cardiovascular outcomes, heart failure, cardio-renal protection, hypertension, and lipid-lowering trials in diabetes and endocrinology.
Summary: In adults with type 2 diabetes, exenatide and glucagon co-infusion significantly increased myocardial glucose uptake and improved markers of…
An exploratory analysis of two Phase 2 trials found that oral orforglipron produced placebo-adjusted reductions in cardiovascular risk biomarkers, not clinical events, in adults with type 2 diabetes or obesity. PICO summary and expert commentary.
A large RCT finds peri-operative exenatide does not reduce death or organ failure after CABG or aortic valve replacement. PICO summary and expert commentary.
A prespecified SOUL trial analysis tested whether baseline SGLT2 inhibitor use modified oral semaglutide’s cardiovascular benefit in type 2 diabetes. PICO summary and expert commentary.
A randomised crossover trial found 60 g/day of mixed nuts for 16 weeks lowered apolipoprotein B and VLDL and LDL particle numbers in older adults with overweight or obesity. PICO summary and expert commentary.
A post-hoc pooled analysis of three phase 3 trials testing tafolecimab 450 mg every four weeks for LDL-C lowering in Chinese adults with type 2 diabetes and hypercholesterolemia. PICO summary and expert commentary.
A small acute mechanistic crossover study testing whether exenatide-glucagon co-infusion raises myocardial glucose uptake and a diastolic strain-rate marker in eight adults with type 2 diabetes. PICO summary and expert commentary.
A double-blind placebo-controlled crossover study finds metformin attenuates the postprandial blood pressure fall and reduces postprandial hypotension events in type 2 diabetes, alongside higher GLP-1, slower gastric emptying, and a faster heart rate. PICO summary and expert commentary.
A secondary analysis of the COORDINATE-Diabetes trial found that up to one-third of patients with Type 2 diabetes and atherosclerotic cardiovascular disease stopped their SGLT-2i or GLP-1RA within 12 months, with cost and side effects among the cited reasons. PICO summary and expert commentary.